ELCELYX THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.elcelyx.com
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- Elcelyx Therapeutics, Inc.
- Target Recruit Count
- 571
- Registration Number
- NCT02526524
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸Tellus Clinical Research, Inc., Miami, Florida, United States
🇺🇸Columbia Medical Practice, Columbia, Maryland, United States
Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- Elcelyx Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02291510
Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-03-27
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Elcelyx Therapeutics, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT01819272
Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2016-10-21
- Lead Sponsor
- Elcelyx Therapeutics, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01804842
Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: EFB0026 (metformin immediate-release)Drug: EFB0027 (metformin delayed release)
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Elcelyx Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01677299
- Locations
- 🇺🇸
Celerion, Inc., Lincoln, Nebraska, United States
Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Elcelyx Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01658514
© Copyright 2025. All Rights Reserved by MedPath